Abstract | BACKGROUND: METHODS: RESULTS: During 2016-2018, 396 patients (aged 12-96 years) were randomized to acetaminophen (n = 199) or no acetaminophen (n = 197). Overall, creatinine fell by a mean (standard deviation) 14.9% (18.1) in the acetaminophen arm vs 14.6% (16.0) in the control arm (P = .81). In severe disease, creatinine fell by 31.0% (26.5) in the acetaminophen arm vs 20.4% (21.5) in the control arm (P = .12), and in those with hemolysis by 35.8% (26.7) and 19% (16.6), respectively (P = .07). No difference was seen overall in patients with AKI; however, in those with AKI and hemolysis, creatinine fell by 34.5% (20.7) in the acetaminophen arm vs 25.9% (15.8) in the control arm (P = .041). Mixed-effects modeling demonstrated a benefit of acetaminophen at 72 hours (P = .041) and 1 week (P = .002) in patients with severe malaria and with AKI and hemolysis (P = .027 and P = .002, respectively). CONCLUSIONS: CLINICAL TRIALS REGISTRATION: NCT03056391.
|
Authors | Daniel J Cooper, Matthew J Grigg, Katherine Plewes, Giri S Rajahram, Kim A Piera, Timothy William, Jayaram Menon, Glenn Koleth, Michael D Edstein, Geoffrey W Birrell, Thanaporn Wattanakul, Joel Tarning, Aatish Patel, Tsin Wen Yeo, Arjen M Dondorp, Nicholas M Anstey, Bridget E Barber |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 75
Issue 8
Pg. 1379-1388
(10 12 2022)
ISSN: 1537-6591 [Electronic] United States |
PMID | 35180298
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. |
Chemical References |
- Hemoglobins
- Acetaminophen
- Creatinine
|
Topics |
- Acetaminophen
(therapeutic use)
- Acute Kidney Injury
(drug therapy)
- Creatinine
- Hemoglobins
(therapeutic use)
- Hemolysis
- Humans
- Kidney
(physiology)
- Malaria
(complications, drug therapy)
- Malaysia
- Plasmodium knowlesi
|